HUC3-637-R
Phase 3Small molecule
HUC3-637-R is one of 17 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Alphagan
NovartisPhase 3
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Azopt
NovartisPhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
Reference - LUMIGAN
AAmneal Pharmaceuticals, LLC
Phase 3
Combigan
EEMS
Phase 3
PRO-122
LLaboratorios Sophia S.A de C.V.
Phase 3
BOL-303259-X
BBausch & Lomb Incorporated
Phase 3
OPC-1085EL
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HUC3-637-R. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHuons Co., Ltd.